Trials / Unknown
UnknownNCT03984045
SPG Block for Acute Pediatric Migraine
Sphenopalatine Ganglion Block for Treating Acute Frontal Migraine Headache in Pediatric Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Newark Beth Israel Medical Center · Academic / Other
- Sex
- All
- Age
- 10 Years – 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.
Detailed description
This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache. Excluded populations include those with sickle cell, concern for CNS infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lidocaine topical | Intranasal 2% lidocaine delivered directly to SPG |
| DRUG | Prochlorperazine Injection | intravenous prochlorperazine at 0.15mg/kg max 10 mg |
Timeline
- Start date
- 2019-06-06
- Primary completion
- 2022-06-30
- Completion
- 2022-12-30
- First posted
- 2019-06-12
- Last updated
- 2021-11-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03984045. Inclusion in this directory is not an endorsement.